These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27324108)

  • 41. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
    Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):323-331. PubMed ID: 27917619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
    Lorusso D; Bologna A; Cecere SC; De Matteis E; Scandurra G; Zamagni C; Arcangeli V; Artioli F; Bella M; Blanco G; Cardalesi C; Casartelli C; De Vivo R; Di Napoli M; Gisone EB; Lauria R; Lissoni AA; Loizzi V; Maccaroni E; Mangili G; Marchetti C; Martella F; Naglieri E; Parolin V; Ricciardi G; Ronzino G; Salutari V; Scarfone G; Secondino S; Spagnoletti I; Tasca G; Tognon G; Guarneri V
    Support Care Cancer; 2020 May; 28(5):2435-2442. PubMed ID: 32048043
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L; Zhong L
    J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
    Venkitaraman AR
    Cancer Cell; 2009 Aug; 16(2):89-90. PubMed ID: 19647219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
    Yonemori K; Tamura K; Kodaira M; Fujikawa K; Sagawa T; Esaki T; Shirakawa T; Hirai F; Yokoi Y; Kawata T; Hatano B; Takahashi Y
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):525-31. PubMed ID: 27422301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
    de Haan R; van Werkhoven E; van den Heuvel MM; Peulen HMU; Sonke GS; Elkhuizen P; van den Brekel MWM; Tesselaar MET; Vens C; Schellens JHM; van Triest B; Verheij M
    BMC Cancer; 2019 Sep; 19(1):901. PubMed ID: 31500595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
    Zhou D; Li J; Learoyd M; Bui K; Berges A; Milenkova T; Al-Huniti N; Tomkinson H; Xu H
    Clin Pharmacol Ther; 2019 Jun; 105(6):1492-1500. PubMed ID: 30585620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
    Im SA; Xu B; Li W; Robson M; Ouyang Q; Yeh DC; Iwata H; Park YH; Sohn JH; Tseng LM; Goessl C; Wu W; Masuda N
    Sci Rep; 2020 May; 10(1):8753. PubMed ID: 32472001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
    de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
    Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    Hilmi M; Neuzillet C
    Bull Cancer; 2020 Oct; 107(10):961-962. PubMed ID: 32943226
    [No Abstract]   [Full Text] [Related]  

  • 53. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. State of art of advanced triple negative breast cancer.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Aparicio Salcedo MI
    Breast J; 2019 Sep; 25(5):967-970. PubMed ID: 31155832
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Olaparib: first global approval.
    Deeks ED
    Drugs; 2015 Feb; 75(2):231-40. PubMed ID: 25616434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
    Kim G; Ison G; McKee AE; Zhang H; Tang S; Gwise T; Sridhara R; Lee E; Tzou A; Philip R; Chiu HJ; Ricks TK; Palmby T; Russell AM; Ladouceur G; Pfuma E; Li H; Zhao L; Liu Q; Venugopal R; Ibrahim A; Pazdur R
    Clin Cancer Res; 2015 Oct; 21(19):4257-61. PubMed ID: 26187614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
    Chen Y; Zhang L; Hao Q
    Arch Gynecol Obstet; 2013 Aug; 288(2):367-74. PubMed ID: 23619942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
    Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer.
    Grabowski JP; Sehouli J; Glajzer J; Worm M; Zuberbier T; Maurer M; Fluhr JW
    N Engl J Med; 2018 Nov; 379(22):2176-2177. PubMed ID: 30485775
    [No Abstract]   [Full Text] [Related]  

  • 60. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
    Frampton JE
    BioDrugs; 2015 Apr; 29(2):143-50. PubMed ID: 25899311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.